Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
HCAR2 338442 CHEMBL2036958 CHEMBL2036958 agonist GuideToPharmacologyInteractions
HCAR2 338442 CHEMBL247132 CHEMBL247132 agonist GuideToPharmacologyInteractions
HCAR2 338442 ACIPIMOX CHEMBL345714 agonist GuideToPharmacologyInteractions
HCAR2 338442 FLOXURIDINE CHEMBL917 agonist GuideToPharmacologyInteractions
HCAR2 338442 COUMARIC ACID CHEMBL66879 agonist GuideToPharmacologyInteractions
HCAR2 338442 CINNAMIC ACID CHEMBL27246 agonist GuideToPharmacologyInteractions
HCAR2 338442 METHYL FUMARATE CHEMBL589586 agonist GuideToPharmacologyInteractions
HCAR2 338442 NIACIN CHEMBL573 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, TTD 16099840, 12646212, 12522134, 15580557, 16018973
HCAR2 338442 CHEMBL1741437 CHEMBL1741437 agonist GuideToPharmacologyInteractions
HCAR2 338442 THYMIDINE CHEMBL52609 agonist GuideToPharmacologyInteractions
HCAR2 338442 ISOETHARINE HYDROCHLORIDE CHEMBL1200920 agonist GuideToPharmacologyInteractions
HCAR2 338442 CHEMBL1086657 CHEMBL1086657 agonist GuideToPharmacologyInteractions
HCAR2 338442 CHEMBL456145 CHEMBL456145 agonist GuideToPharmacologyInteractions
HCAR2 338442 BUTANOIC ACID CHEMBL14227 agonist GuideToPharmacologyInteractions
HCAR2 338442 ACIFRAN CHEMBL278488 agonist GuideToPharmacologyInteractions
HCAR2 338442 MEPENZOLATE CHEMBL524004 TdgClinicalTrial, TEND

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
HCAR2 rs7314976 AA + AG niacin efficacy no The study compared statin + placebo treated patients with statin + extended release niacin treated patients from the from the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) trial. No association of this variant (p.M317I) with changes in low-density lipoprotein cholesterol, triglycerides, lipoprotein a or high-density lipoprotein cholesterol at 1 year were found. Genotypes AA + AG is not associated with response to niacin as compared to genotype GG. 28628560 1448635810
HCAR2 rs2454727 CT + TT niacin efficacy yes The study compared statin + placebo treated patients with statin + extended release niacin treated patients from the from the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) trial. In White patients, the reduction in lipoprotein (a) [Lp(a)] in response to niacin was greater in subjects with the CC genotype. Genotypes CT + TT is associated with decreased response to niacin as compared to genotype CC. 28628560 1448635792
HCAR2 rs2454727 CT + TT niacin efficacy no The study compared statin + placebo treated patients with statin + extended release niacin treated patients from the from the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) trial. No association of this variant (p.M317I) with changes in low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol at 1 year were found. Genotypes CT + TT is not associated with response to niacin as compared to genotype CC. 28628560 1448635798